ARTICLE | Clinical News
OXPzero Naproxen: Phase I data
August 10, 2015 7:00 AM UTC
An open-label, U.K. Phase I trial in patients with upper gastrointestinal tract irritation showed that 250 mg OXP005 missed the co-primary endpoints of reducing the severity of gastroduodenal irritati...